BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The group expects to raise nearly $170m.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.